Angew Chem Int Ed, 2022, 61: e202204291 Huang Y, Wu S, Zhang L, et al
Nat Cell Biol (2011) 13(3):3106
If you experience any unexpected symptoms whilst participating in a trial, you should: Contact your trial coordinator immediately, as trial participants must report adverse events through their study team Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk if appropriate Seek urgent medical attention if symptoms are severe Current Availability and Regulatory Status in the UK Neither cagrilintide nor retatrutide holds MHRA marketing authorisation in the UK
Exenatide may promote differentiation of pancreatic ductal cells to a beta-cell phenotype in baboons without inducing pancreatitis, accumulation of parenchymal or periductal inflammatory cells, ductal hyperplasia, dysplastic lesions, or pancreatic intraepithelial neoplasia [26]
Without the medication, the hormonal environment actively promotes weight regain
Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al
